| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 09/06/2002 | WO2002067896A1 Ibutilide and methanesulfonamide for local anesthetics |
| 09/06/2002 | WO2002067895A2 Implant dosage form and use thereof for the delivery of a cholesterol lowering agent |
| 09/06/2002 | WO2002067893A2 Pharmaceutical formulation comprising bicalutamide |
| 09/06/2002 | WO2002067891A1 Free nicotine based cosmetic composition and uses thereof |
| 09/06/2002 | WO2002067890A2 Method and product for skin lightening |
| 09/06/2002 | WO2002067886A2 Skin composition |
| 09/06/2002 | WO2002067885A2 Photoprotecting formulations |
| 09/06/2002 | WO2002067880A1 Treatment of dandruff |
| 09/06/2002 | WO2002067879A2 Material composition and oral galenic form against hair loss and brittle nails |
| 09/06/2002 | WO2002067878A2 Use of mil thistle extract in skin care compositions |
| 09/06/2002 | WO2002067870A2 Composition and method for preventing and treating sinusoidal obstruction syndrome and radiation-induced liver disease |
| 09/06/2002 | WO2002067869A2 Acylated piperidine derivatives as melanocortin-4 receptor agonists |
| 09/06/2002 | WO2002067866A2 Piperazine derivatives as metalloprotease inhibitors |
| 09/06/2002 | WO2002067865A2 N-(aryl)-2-arylethenesulfonamides and therapeutic uses thereof |
| 09/06/2002 | WO2002067864A2 Coenzyme q products exhibiting high dissolution qualities |
| 09/06/2002 | WO2002067854A2 Manufacture of thyroid hormone tablets having consistent active moiety amounts |
| 09/06/2002 | WO2002067853A2 A combination and method of treatment of hiv and viral diseases, vascular disease and cancer utilizing a cox-2 inhibitor and cystine |
| 09/06/2002 | WO2002067851A2 Method for treating fibrotic diseases or other indications iiic |
| 09/06/2002 | WO2002067831A1 Composition for freshening nostrils and sinus cavities |
| 09/06/2002 | WO2002067698A1 Process for the fractionation of cereal brans |
| 09/06/2002 | WO2002067688A1 Noninvasive measurements of chemical substances |
| 09/06/2002 | WO2002067683A1 Hiv protease inhibitors supported on cation exchange resins for oral administration |
| 09/06/2002 | WO2002067681A1 Restore cancer-suppressing functions to neoplastic cells through dna hypomethylation |
| 09/06/2002 | WO2002067654A2 6-substituted pyrazolo[3,4-d]pyrimidin-4-ones useful as cyclin dependent kinase inhibitors |
| 09/06/2002 | WO2002067651A2 Pharmaceutical salts |
| 09/06/2002 | WO2002055089A3 Immunoassay technique using multispecific molecules |
| 09/06/2002 | WO2002055079A3 Aza-and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors |
| 09/06/2002 | WO2002055059A3 Method for preparing submicron particle suspensions |
| 09/06/2002 | WO2002053094A3 Method for detoxifying a carbohydrate containing solution |
| 09/06/2002 | WO2002051832A3 Heterocyclylalkylindole or -azaindole compounds as 5-hydroxytryptamine-6 ligands |
| 09/06/2002 | WO2002050029A3 Tetracyclic derivatives as spla2 inhibitors |
| 09/06/2002 | WO2002050024A3 Thiazolidinediones |
| 09/06/2002 | WO2002046415A9 Polynucleotide and polypeptide sequences of putative transporters and ion channells |
| 09/06/2002 | WO2002046183A3 Indazolyl-substituted pyrroline compounds as kinase inhibitors |
| 09/06/2002 | WO2002044170A3 Benzothiophene derivative compounds, process of preparation and use thereof |
| 09/06/2002 | WO2002043716A3 Method for regulating prostate gland volume with insulin sensitizers |
| 09/06/2002 | WO2002043659A3 Composition containing statins and calcium for improved cardiovascular health |
| 09/06/2002 | WO2002043654A3 Pharmaceutical composition and method for treatment of brain injury, spinal cord injury, stroke, neurodegenerative disease and other conditions |
| 09/06/2002 | WO2002043648A8 Compounds active at the glucocorticoid receptor ii |
| 09/06/2002 | WO2002041882A3 Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity |
| 09/06/2002 | WO2002041832A3 Compositions having comfrey and methods for reducing retinoid-induced skin irritation |
| 09/06/2002 | WO2002040062A3 Improved ophthalmic and contact lens solutions with a peroxide source and a cationic polymeric preservative |
| 09/06/2002 | WO2002040000A3 Use of cci-779 as an antineoplastic agent |
| 09/06/2002 | WO2002039958A3 Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents |
| 09/06/2002 | WO2002038563A3 Condensed pyrazindione derivatives as pde inhibitors |
| 09/06/2002 | WO2002036771A3 Imaging, diagnosis and treatment of disease |
| 09/06/2002 | WO2002032868A3 2-substituted heterocyclic compounds and their use in treating multidrug resistance |
| 09/06/2002 | WO2002032421A8 Indole compounds as minimally physiologial function monitioring agents |
| 09/06/2002 | WO2002030405A3 Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance |
| 09/06/2002 | WO2002028860A3 Amino-substituted tetracyclic compounds useful as anti-inflammatory agents and pharmaceutical compositions comprising same |
| 09/06/2002 | WO2002024185A3 Topical analgesic compositions containing aliphatic polyamines and methods of using same |
| 09/06/2002 | WO2002023995A8 Method of blocking free radical processes which result in media ted pathology without deleterious pro-oxidant side reactions |
| 09/06/2002 | WO2002022577A3 Hydroxamate derivatives useful as deacetylase inhibitors |
| 09/06/2002 | WO2002022146A8 Components of canola for treating hyperlipidemia |
| 09/06/2002 | WO2002019985A3 Methods for inhibiting decrease in transdermal drug flux by inhibition of pathway closure |
| 09/06/2002 | WO2002019972A3 Stabilized ascorbic acid solutions |
| 09/06/2002 | WO2002017890A3 Treatment of arthritis and compositions therefore containing a n-acylated-2-glucosamine derivative |
| 09/06/2002 | WO2002012534A3 Bio-intermediates for use in the chemical synthesis of polyketides |
| 09/06/2002 | WO2002012250A3 Pyrazole-thiazole compounds, pharmaceutical compositions containing them, and methods of their use for inhibiting cyclin-dependent kinases |
| 09/06/2002 | WO2002011746A3 Chlorella preparations exhibiting immunomodulating properties |
| 09/06/2002 | WO2002008475A3 Method for recovery of copper from sulfidic ore materials using super-fine grinding and medium temperature pressure leaching |
| 09/06/2002 | WO2002007823A3 Inhibition of mutagenic effects of carcinogens |
| 09/06/2002 | WO2002007726A3 Treatment of movement disorders |
| 09/06/2002 | WO2002007714A3 Use of anellated dihydropyridines for the preparation of pharmaceutical compositions for the treatment of chronic pain |
| 09/06/2002 | WO2002005796A3 Use of a spla2 inhibitor for the treatment of sepsis |
| 09/06/2002 | WO2002005793A3 Use of fluorescein derivatives for the treatment of diseases responsive to the activation of the cystic fibrosis transmembrane conductance regulator chloride channel |
| 09/06/2002 | WO2001095946A3 Combination product for carrying out a cytotoxic treatment in a mammal |
| 09/06/2002 | WO2001095937A3 Phytoestrogenic isoflavone compositions |
| 09/06/2002 | WO2001094612A3 Method for identifying medically valuable active substances |
| 09/06/2002 | WO2001092565A3 Diagnosis of diseases associated dna transcription by means of assessing the methylation status of genes associated with dna transcription |
| 09/06/2002 | WO2001091738A3 Naaladase inhibitors for treating amyotrophic lateral sclerosis |
| 09/06/2002 | WO2001082910A3 Combination of progesterone and mifepristone for cancer therapy |
| 09/06/2002 | WO2001072822B1 Genes involved in intestinal inflammatory diseases and use thereof |
| 09/06/2002 | WO2001070203A3 Agent for treating hepatitis c containing ukrain |
| 09/06/2002 | WO2001058915A8 Human g-protein chemokine receptor (ccr5) hdgnr10 |
| 09/06/2002 | WO2001049687A9 Cyclohexene nucleic acids |
| 09/06/2002 | WO2001041751A3 Phytoestrogens for treating als |
| 09/06/2002 | WO2001037814A9 Bilayered buccal tablets comprising nicotine |
| 09/06/2002 | WO2001032614A9 Novel genes tzap7/a, tzap7/b and tzap7 involved in t cell activation and uses thereof |
| 09/06/2002 | WO2001031021A9 Multiple sclerosis-related superantigen |
| 09/06/2002 | WO2001024792A9 Synergistic combinations of an nk1 receptor antagonist and a gaba structural analog |
| 09/06/2002 | WO2001018546A9 Screening for inhibitors of 'paired helical filaments' |
| 09/06/2002 | WO2001018035A9 Muc-1 derived peptides |
| 09/06/2002 | WO2001018011A9 Calcium complex of phosphorus containing ethylenediamine derivatives |
| 09/06/2002 | WO2001015553A9 Dietary food supplement containing natural cyclooxygenase inhibitors |
| 09/06/2002 | WO2001012170A3 Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue |
| 09/06/2002 | CA2753395A1 Novel bifunctional chelating compounds containing hydroxamic acid residues |
| 09/06/2002 | CA2725635A1 Pharmaceutical salts of 6-dimethylaminomethyl-1-phenylcyclohexane compounds |
| 09/06/2002 | CA2617312A1 Noninvasive measurement of chemical substances |
| 09/06/2002 | CA2617004A1 Noninvasive measurements of chemical substances |
| 09/06/2002 | CA2475454A1 Aryl-n-cyanoguanidines and methods related thereto |
| 09/06/2002 | CA2439468A1 New crystal forms of lamotrigine and processes for their preparations |
| 09/06/2002 | CA2439465A1 Prophylactic teat treatment |
| 09/06/2002 | CA2439463A1 Diaminoquinazoline esters for use as dihydrofolate reductade inhibitors |
| 09/06/2002 | CA2439376A1 Compositions and methods of manufacture for oral dissolvable dosage forms |
| 09/06/2002 | CA2439366A1 Pharmaceutical formulation comprising bicalutamide |
| 09/06/2002 | CA2439335A1 Interferon regulatory factor-1/human estrogen receptor fusion protein and its use for treating carcinomas |
| 09/06/2002 | CA2439299A1 Metronomic dosing of taxanes |
| 09/06/2002 | CA2439298A1 Methods and reagents to acquire mri signals and images |
| 09/06/2002 | CA2439292A1 Carbamate compounds for use in preventing or treating bipolar disorder |